Esthesioneuroblastoma: a brief review of literature in the context of a case report
Keywords:
esthesioneuroblastoma, nose neoplasms, radiotherapy, chemotherapyAbstract
Esthesioneuroblastoma is an uncommon neoplasia that arises from the olfactory neuroepithelium and corresponds to 3-6% of all intranasal malignant tumors. The symptoms are nonspecific and common to other pathologies of the nasal cavity. There are no guidelines regarding its treatment. The few available studies observed good outcomes with a multimodal approach.
We report the case of a young woman diagnosed with esthesioneuroblastoma, stage C of modified Kadish. The patient presented a partial response after 4 cycles of chemotherapy (cisplatin and etoposide). Then, she was proposed for radical chemoradiotherapy (66-70 Gy of radiotherapy and 3 cycles of cisplatin), with no evidence of disease at the end of treatment, remaining disease-free 1.5 years after.
The multimodal approach has good outcomes in the treatment of esthesioneuroblastoma, as observed in the reported clinical case, with complete response to combined treatment of chemotherapy and radiotherapy.
Downloads
References
Spiro JD, Soo KC, Spiro RH. Nonsquamous cell malignant neoplasms of the nasal cavities and paranasal sinuses. Head Neck. 1995;17(2):114-8. doi: 10.1002/hed.2880170207.
Broich G, Pagliari A, Ottaviani F. Esthesioneuroblastoma: a general review of the cases published since the discovery of the tumour in 1924. Anticancer Res. 1997;17(4A):2683-706.
Fiani B, Quadri SA, Cathel A, Farooqui M, Ramachandran A, Siddiqi I, et al. Esthesioneuroblastoma: a comprehensive review of diagnosis, management, and current treatment options. World Neurosurg. 2019;126:194-211. doi: 10.1016/j.wneu.2019.03.014.
Bachar G, Goldstein DP, Shah M, Tandon A, Ringash J, Pond G, et al. Esthesioneuroblastoma: The Princess Margaret Hospital experience. Head Neck. 2008; 30(12):1607-14. doi: 10.1002/hed.20920.
Su SY, Bell D, Hanna EY. Esthesioneuroblastoma, neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma: differentiation in diagnosis and treatment. Int Arch Otorhinolaryngol. 2014; 18:S149-56. doi: 10.1055/s-0034-1390014.
Kumar R. Esthesioneuroblastoma: multimodal management and review of literature. World J Clin Cases. 2015; 3(9):774-8. doi: 10.12998/wjcc.v3.i9.774.
Pickuth D, Heywang-Kobrunner SH, Spielmann RP. Computed tomography and magnetic resonance imaging features of olfactory neuroblastoma: an analysis of 22 cases. Clin Otolaryngol Allied Sci. 1999; 24(5):457-61. doi: 10.1046/j.1365-2273.1999.00295.x.
Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology and genetics of head and neck tumours. World Health Organization Classification of tumours. Lyon, France: IARC Press; 2005. p 66-70.
Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer. 1976; 37(3):1571-76. doi: 10.1002/1097-0142(197603)37:3<1571::AID-CNCR2820370347>3.0.CO;2-L.
Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, Quast LM. Esthesioneuroblastoma: prognosis and management. Neurosurgery. 1993; 32(5):706-14. doi: 10.1227/00006123-199305000-00002.
American Joint Committee on Cancer; American College of Surgeons. AJCC Cancer Staging Manual. AJCC Cancer Staging Form Supplemen, 8th ed. Chicago, USA: AJCC; 2018. p. 46-51.
Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol. 2001; 2(11):683-90. doi: 10.1016/S1470-2045(01)00558-7.
Foote RL, Morita A, Ebersold MJ, Olsen KD, Lewis JE, Quast LM, et al. Esthesioneuroblastoma: the role of adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 1993; 27(4):835-42. doi: 10.1016/0360-3016(93)90457-7.
Patil VM, Joshi A, Noronha V, Sharma V, Zanwar S, Dhumal S, et al. Neoadjuvant chemotherapy in locally advanced and borderline resectable nonsquamous sinonasal tumors (esthesioneuroblastoma and sinonasal tumor with neuroendocrine differentiation). Int J Surg Oncol. 2016; 6923730:1-8. doi: 10.1155/2016/6923730.
Mishima Y, Nagasaki E, Terui Y, Irie T, Takahashi S, Ito Y, et al. Combination chemotherapy (cyclophosphamide, doxorrubicin, and vincristine with continuous-infusion cisplatin and etoposide) and radiotherapy with stem cell support can be beneficial for adolescents and adults with esthesioneuroblastoma. Cancer. 2004; 101(6):1437-44. doi: 10.1002/cncr.20471.
Bhattacharyya N, Thornton AF, Joseph MP, Goodman ML, Amrein PC. Successful treatment of esthesioneuroblastoma and neuroendocrine carcinoma with combined chemotherapy and proton radiation - results in 9 cases. Arch Otolaryngol Head Neck Surg. 1997; 123(1):34-40. doi: 10.1001/archotol.1997.01900010038005.
